Results of quinacrine administration to patients with Creutzfeldt-Jakob disease

Dementia and Geriatric Cognitive Disorders

Volumn 17, Issue 3, 2004, Pages 158-163

  Nakajima, Masashi ^a,b   Yamada, Tatsuo ^a   Kusuhara, Tomohiko ^a   Furukawa, Hisako ^a   Takahashi, Mitsuo ^a   Yamauchi, Atsushi ^a   Kataoka, Yasufumi ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b TOKYO ROSAI HOSPITAL   (Japan)

Author keywords

Creutzfeldt Jakob disease; Prion; Quinacrine

Indexed keywords

AMINOTRANSFERASE; ANTIMALARIAL AGENT; MEPACRINE; PRION PROTEIN;

ADULT; AKINETIC MUTISM; AMINOTRANSFERASE BLOOD LEVEL; AROUSAL; ARTICLE; CASE REPORT; CREUTZFELDT JAKOB DISEASE; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; EYE MOVEMENT; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; IATROGENIC DISEASE; JAUNDICE; LIVER DYSFUNCTION; MALE; PATIENT; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; VERBALIZATION; VISUAL STIMULATION; VOLUNTARY MOVEMENT;

ANTIMALARIALS; CREUTZFELDT-JAKOB SYNDROME; ELECTROENCEPHALOGRAPHY; EYE MOVEMENTS; FEMALE; HEAD MOVEMENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOVEMENT; MYOCLONUS; QUINACRINE;

EID: 1542405248     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076350     Document Type: Article

References (16)

1. Prusiner SB, Hsiao KK: Human prion diseases. Ann Neurol 1994;35:385-395.
2. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-925.
3. Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts - Japan, January 1979-May 1996. MMWR Morb Mortal Wkly Rep 1997;46:1066-1069.
4. Doh-Ura K, Iwaki T, Caughey B: Lysosomototropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000;74:4894-4897.
5. Korth C, May BC, Cohen FE, Prusiner SB: Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-9841.
6. Lidz T, Kahn RL: Toxicity of quinacrine (atabrine) for the central nervous system. III. An experimental study on human subjects. Arch Neurol Psychiatry 1946;56:284-299.
7. Rolls IM: Drugs used in the chemotherapy of helminthiasis; in Goodman LS, Gillman A (eds): Pharmacological Basis of Therapeutics, ed 5. New York, Macmillan, 1975, pp 1080-1094.
8. Shannon JA, Earle DP, Brodie BB, Taggart JV, Berliner RW: The pharmacological basis for the rational use of atabrine in the treatment of malaria. J Pharmacol Exp Ther 1944;81:307-330.
9. Brandel J-P, Delasnerie-Lauprêtre N, Laplanche J-L, Hauw J-J, Alpérovitch A: Diagnosis of Creutzfeldt-Jakob disease: Effect of clinical criteria on incidence estimates. Neurology 2000;54:1095-1099.
10. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters C: Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002;52:503-506.
11. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H: Classification of sporadic Creutzfeldt-Jacob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224-233.
12. Moseley ME, Butts K: Diffusion and perfusion; in Stark DD, Bradley WG Jr (eds): Magnetic Resonance Imaging. St. Louis, Mosby, 1999, p 1515.
13. Mittal S, Farmer P, Kalina P, Kingsley PB, Halperin J: Correlation of diffusion-weighted magnetic resonance imaging with neuropathology in Creutzfeldt-Jakob disease. Arch Neurol 2002;59:128-134.
14. Shimizu S, Hoshi K, Muramoto T, Homma M, Ironside JW, Kuzuhara S, Sato T, Yamamoto T, Kitamoto T: Creutzfeldt-Jakob disease with florid-type plaques after cadaveric dura mater grafting. Arch Neurol 1999;56:357-362.
15. Lindenmayer J-P, Vargas P: Toxic psychosis following use of quinacrine. J Clin Psychiatry 1981;42:162-164.
16. Engel GL, Romano J, Ferris EB: Effect of quinacrine (atabrine) on the central nervous system, clinical and electroencephalographic studies. Arch Neurol Psychiatry 1947;58:337-350.